Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10689485 | 0.86 | ALDH1A1 (0.46) | ALDH1A1CYP3A4MAPTHPGDKDM4E | |
| SCHEMBL5157568 | 0.81 | HPGD (0.47) | ALDH1A1CYP3A4MAPTHPGDSMN1; SMN2 | |
| SCHEMBL5154978 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CYP3A4MAPTHPGDKDM4E | |
| Flutonidine SCHEMBL5154947 | 0.79 | NISCH (0.41) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL5157866 | 0.78 | ITGB3 (0.40) | CYP3A4MAPTHPGDSMN1; SMN2AHR | |
| Hydrochloric Acid SCHEMBL11018810 | 0.77 | ALDH1A1 (0.41) | ALDH1A1CYP3A4MAPTHPGDKDM4E | |
| SCHEMBL11450479 | 0.76 | — | — | |
| SCHEMBL11375823 | 0.75 | AHR (0.32) | AHRHTR2AHTR2CHTR2B | |
| SCHEMBL11371070 | 0.75 | TAAR1 (0.34) | CYP3A4MAPTHPGDSMN1; SMN2CYP2C19 | |
| SCHEMBL11356667 | 0.73 | MAPT (0.38) | ALDH1A1MAPTKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981498-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-la Roche AG (CH) | 2008-10-22 | — | — | EP | claimed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | claimed |
| EP-1981498-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. Hoffmann-la Roche AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | HOFFMANN-LA ROCHE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090720-A2 | USE OF 2-IMIDAZOLES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197569-A1 | Method for treating central nervous system disorders with substituted 2-imidazoline derivatives | CRY1, HTR2C, PER2 | ALDH1A1 867/4885CYP3A4 98/4885MAPT 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.